<head>
<title>Core Laboratories N.V. 8K Earnings Release</title>
</head>

<html>

<body>

<b><font SIZE="2">
</font><font SIZE="4">
<p ALIGN="CENTER">UNITED STATES</p>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</p>
</font><font SIZE="2">
<p ALIGN="CENTER">Washington, D.C. 20549</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">________________</p>
</font><b><font SIZE="5">
<p ALIGN="CENTER">FORM 8-K</p>
</font></b>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="684">
  <tr>
    <td VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">
      <p>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934</font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">Date of report:<b>
      October 31, 2006  </b></font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
</font><b><font FACE="Times" SIZE="5">
<p ALIGN="CENTER">CORE LABORATORIES N.V.</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">(Exact name of registrant as specified in its charter)</p>
<p ALIGN="CENTER"><b>001-14273<br>
</b>(Commission File Number)</p>
</font>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680">
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(State or other jurisdiction of incorporation or
      organization)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(I.R.S. Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Herengracht 424</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">1017 BZ Amsterdam</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Address of principal executive offices)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Zip Code)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p ALIGN="CENTER">Registrant's telephone number, including area code: <b>(31-20)
420-3191</b></p>
<p ALIGN="CENTER">&nbsp;</p>
<p ALIGN="left"><font SIZE="2">Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </font></p>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680" style="border-left-width: 0; border-top-width: 0; border-bottom-width: 0">
  <tr>
    <td WIDTH="44" style="border-style: none; border-width: medium">
    <p align="center">___</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Written communications
    pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      <font SIZE="2">
      <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Soliciting material
      pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Pre-commencement
      communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Pre-commencement
    communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      &nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
</table>
<hr>
<p>&nbsp;</p>
<b><P>Item 8.01  Other Events </P>
</b>
<p>On October 31, 2006, Core Laboratories N.V. (&quot;Core Lab&quot;) announced that its
U.S.-based, wholly owned subsidiary, Core Laboratories L.P. (&quot;Core LP&quot;), intends
to offer, subject to market and other conditions, approximately $250 million
aggregate principal amount of senior exchangeable notes due 2011 through an
offering within the United States to qualified institutional buyers pursuant to
Rule 144A under the Securities Act of 1933, as amended  (the &quot;Securities Act&quot;).
The notes will be fully and unconditionally guaranteed by Core Lab and
exchangeable under certain circumstances. Upon exchange, holders will receive
cash up to the principal amount, and any excess exchange value will be delivered
in Core Lab's common shares. Core LP also expects to grant the initial
purchasers of the notes a 13-day option to purchase additional notes to cover overallotments in an amount not to exceed $50 million.</p>
<p>Core LP intends to use a portion of the net proceeds from the offering for
the cost of the exchangeable note hedge transactions that CLLP expects to enter
into with one or more financial institutions, which may include affiliates of
the initial purchasers. The exchangeable note hedge transactions are intended to
limit exposure to potential dilution to Core Lab shareholders from exchanging
the notes. The remaining net proceeds of the offering will be used for to repay
outstanding amounts under the Company's revolving credit facility and to
repurchase up to 2,100,000 of Core Lab's common shares. In addition, in
connection with the repayment of the revolving credit facility, Core Lab intends
to amend the terms of the credit facility to reduce the commitments under the
facility from $125 million to between $50 and&nbsp; 90 million.</p>

<P> In connection with this offering, we have included an additional disclosure to our previously filed consolidated financial statements referenced below, which includes condensed consolidating financial information presenting supplemental information for (a) Core NV as parent/guarantor, (b) Core LP, issuer of Notes guaranteed by Core NV, (c) the non-guarantor subsidiaries, (d) consolidating adjustments necessary to consolidate Core NV and its subsidiaries and (f) Core NV on a consolidated basis.  Exhibit 99.2 to this Current Report on Form 8-K, gives effect to the foregoing within our historical consolidated financial statements for the three years ended December 31, 2005, 2004 and 2003 and Exhibits
99.3, 99.4 and 99.5 gives effect to the foregoing within our historical consolidated financial statements for the quarterly periods ended March 31, June 30, and September 30, 2006,
respectively.  These condensed consolidating financial statements do not otherwise amend, update or change any items or disclosures contained in Core NV's previously filed annual reports or quarterly reports.</P>

<b><p><font SIZE="2">Item 9.01 Financial Statements and Exhibits</font></p>
<table class="MsoNormalTable" style="width: 468.75pt" cellSpacing="0" cellPadding="0" width="625" border="0">
  <tr>
    <td style="width: 4%; padding: 0in" width="4%">&nbsp;</td>
    <td style="width: 4%; padding: 0in" width="4%">
    <p style="text-align: center" align="right"><font SIZE="2">(d)</font></td>
    <td style="width: 1%; padding: 0in" width="1%">&nbsp;</td>
    <td style="width: 91%; padding: 0in" width="91%"><i>
    <font SIZE="2">Exhibits</font></i></td>
  </tr>
</table>
<P ALIGN="CENTER"><CENTER>
<TABLE CELLSPACING=0 BORDER=0 WIDTH="65%" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
<TR><TD WIDTH="14%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
  <TD WIDTH="14%" VALIGN="BOTTOM" style="border-bottom-style: solid; border-bottom-width: 1">
<P align="center"><b><font SIZE="2">
      EXHIBIT NO.</font></b></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="BOTTOM" style="border-bottom-style: solid; border-bottom-width: 1">
<P><b><font SIZE="2">
      ITEM</font></b></TD>
</TR>
<TR>
  <TD WIDTH="14%" VALIGN="TOP" style="border-top-style: solid; border-top-width: 1">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP" style="border-top-style: solid; border-top-width: 1">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>23.1 </FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>Consent of Independent Registered Public Accounting Firm.</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<tr>
  <TD WIDTH="14%" VALIGN="TOP" align="center">
<font size="2">99.1</font></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
<font SIZE="2">Press release issued on October 31, 2006</font></TD>
</tr>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>99.2 </FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>Core Laboratories N.V. Audited Consolidated Financial Statements for the fiscal years ended December&nbsp;31, 2005, 2004 and 2003.</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>99.3</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>Core Laboratories N.V. Consolidated Financial Statements for the quarterly period ended March 31, 2006.</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<font size="2">99.4</font></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
<font SIZE="2">
Core Laboratories N.V. Consolidated<b> </b>Financial Statements for the quarterly period ended June 30,&nbsp; 2006.</font></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<font size="2">99.5</font></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
<font SIZE="2">
Core Laboratories N.V. Consolidated<b> </b>&nbsp;Financial Statements for the quarterly period ended September 30, 2006.</font></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
</TABLE>
</CENTER>
<p></p>
<hr>
<p ALIGN="CENTER">SIGNATURES</b></p>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>
<center>
<div align="right">
<table BORDER="0" CELLSPACING="0" WIDTH="635" cellpadding="0">
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="48%" VALIGN="bottom" COLSPAN="5"><font SIZE="2">
      <p>Core Laboratories N.V.</font></td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom"><font SIZE="2">
      <p>Dated: October 31, 2006</font></td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom"><font SIZE="2">
      <p>By</font></td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p style="border-bottom-style: solid; border-bottom-width: 1">/s/ Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p>Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p>Chief Financial Officer</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
</table>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<hr>
</font>
<b><font SIZE="2">
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C. 20549</font></b></p>
<font SIZE="2"><b>
<p ALIGN="CENTER">CORE LABORATORIES N.V.<br>
EXHIBIT INDEX TO FORM 8-K</b></p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>

<b>
<P ALIGN="CENTER"><CENTER>
<div align="left">
<TABLE CELLSPACING=0 BORDER=0 WIDTH="65%" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
<TR><TD WIDTH="14%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR>
  <TD WIDTH="14%" VALIGN="BOTTOM" style="border-bottom-style: solid; border-bottom-width: 1">
<P align="center"><b><font SIZE="2">
      EXHIBIT NO.</font></b></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="BOTTOM" style="border-bottom-style: solid; border-bottom-width: 1">
<P><b><font SIZE="2">
      ITEM</font></b></TD>
</TR>
<TR>
  <TD WIDTH="14%" VALIGN="TOP" style="border-top-style: solid; border-top-width: 1">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP" style="border-top-style: solid; border-top-width: 1">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>23.1 </FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>Consent of Independent Registered Public Accounting Firm.</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<tr>
  <TD WIDTH="14%" VALIGN="TOP" align="center">
<font size="2">99.1</font></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
<font SIZE="2">Press release issued on October 31, 2006</font></TD>
</tr>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>99.2 </FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>Core Laboratories N.V. Audited Consolidated Financial Statements for the fiscal years ended December&nbsp;31, 2005, 2004 and 2003.</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<FONT SIZE=2><P>99.3</FONT></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
<FONT SIZE=2><P>&nbsp;</FONT></TD>
<TD WIDTH="81%" VALIGN="TOP">
<FONT SIZE=2><P>Core Laboratories N.V. Consolidated<b> </b>&nbsp;Financial Statements for the quarterly period ended March 31, 2006.</FONT></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<font size="2">99.4</font></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
<font SIZE="2">
Core Laboratories N.V. Consolidated<b> </b>Financial Statements for the quarterly period ended June 30,&nbsp; 2006.</font></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
<font size="2">99.5</font></TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
<font SIZE="2">
Core Laboratories N.V. Consolidated<b> </b>&nbsp;Financial Statements for the quarterly period ended September 30, 2006.</font></TD>
</TR>
<TR><TD WIDTH="14%" VALIGN="TOP" align="center">
&nbsp;</TD>
<TD WIDTH="5%" VALIGN="BOTTOM">
&nbsp;</TD>
<TD WIDTH="81%" VALIGN="TOP">
&nbsp;</TD>
</TR>
</TABLE>
</div>
</CENTER>
<p></p>
</b>
</font>

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "clb-8k_revisedfilings.htm", "description": "8-K", "secsgml_size_bytes": 20877}]
{"company-data": {"conformed-name": "CORE LABORATORIES N V", "cik": "0001000229", "assigned-sic": "1389", "irs-number": "000000000", "state-of-incorporation": "P7", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14273", "film-number": "061173916"}, "business-address": {"street1": "1017 BZ AMSTERDAM", "street2": "HERENGRACHT 424", "city": "THE NETHERLANDS", "state": "P7", "phone": "3124203191"}, "mail-address": {"street1": "6316 WINDFERN", "city": "HOUSTON", "state": "TX", "zip": "77040"}}
Core Laboratories N.V. 8K Earnings Release
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
Date of report:
October 31, 2006
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
001-14273
(Commission File Number)
The Netherlands
Not Applicable
(State or other jurisdiction of incorporation or
      organization)
(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(31-20)
420-3191
Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
___
Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
___
Soliciting material
      pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
___
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))
___
Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))
Item 8.01  Other Events
On October 31, 2006, Core Laboratories N.V. ("Core Lab") announced that its
U.S.-based, wholly owned subsidiary, Core Laboratories L.P. ("Core LP"), intends
to offer, subject to market and other conditions, approximately $250 million
aggregate principal amount of senior exchangeable notes due 2011 through an
offering within the United States to qualified institutional buyers pursuant to
Rule 144A under the Securities Act of 1933, as amended  (the "Securities Act").
The notes will be fully and unconditionally guaranteed by Core Lab and
exchangeable under certain circumstances. Upon exchange, holders will receive
cash up to the principal amount, and any excess exchange value will be delivered
in Core Lab's common shares. Core LP also expects to grant the initial
purchasers of the notes a 13-day option to purchase additional notes to cover overallotments in an amount not to exceed $50 million.
Core LP intends to use a portion of the net proceeds from the offering for
the cost of the exchangeable note hedge transactions that CLLP expects to enter
into with one or more financial institutions, which may include affiliates of
the initial purchasers. The exchangeable note hedge transactions are intended to
limit exposure to potential dilution to Core Lab shareholders from exchanging
the notes. The remaining net proceeds of the offering will be used for to repay
outstanding amounts under the Company's revolving credit facility and to
repurchase up to 2,100,000 of Core Lab's common shares. In addition, in
connection with the repayment of the revolving credit facility, Core Lab intends
to amend the terms of the credit facility to reduce the commitments under the
facility from $125 million to between $50 and  90 million.
In connection with this offering, we have included an additional disclosure to our previously filed consolidated financial statements referenced below, which includes condensed consolidating financial information presenting supplemental information for (a) Core NV as parent/guarantor, (b) Core LP, issuer of Notes guaranteed by Core NV, (c) the non-guarantor subsidiaries, (d) consolidating adjustments necessary to consolidate Core NV and its subsidiaries and (f) Core NV on a consolidated basis.  Exhibit 99.2 to this Current Report on Form 8-K, gives effect to the foregoing within our historical consolidated financial statements for the three years ended December 31, 2005, 2004 and 2003 and Exhibits
99.3, 99.4 and 99.5 gives effect to the foregoing within our historical consolidated financial statements for the quarterly periods ended March 31, June 30, and September 30, 2006,
respectively.  These condensed consolidating financial statements do not otherwise amend, update or change any items or disclosures contained in Core NV's previously filed annual reports or quarterly reports.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits
EXHIBIT NO.
ITEM
23.1
Consent of Independent Registered Public Accounting Firm.
99.1
Press release issued on October 31, 2006
99.2
Core Laboratories N.V. Audited Consolidated Financial Statements for the fiscal years ended December 31, 2005, 2004 and 2003.
99.3
Core Laboratories N.V. Consolidated Financial Statements for the quarterly period ended March 31, 2006.
99.4
Core Laboratories N.V. Consolidated
Financial Statements for the quarterly period ended June 30,  2006.
99.5
Core Laboratories N.V. Consolidated
Financial Statements for the quarterly period ended September 30, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Core Laboratories N.V.
Dated: October 31, 2006
By
/s/ Richard L. Bergmark
Richard L. Bergmark
Chief Financial Officer
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
EXHIBIT NO.
ITEM
23.1
Consent of Independent Registered Public Accounting Firm.
99.1
Press release issued on October 31, 2006
99.2
Core Laboratories N.V. Audited Consolidated Financial Statements for the fiscal years ended December 31, 2005, 2004 and 2003.
99.3
Core Laboratories N.V. Consolidated
Financial Statements for the quarterly period ended March 31, 2006.
99.4
Core Laboratories N.V. Consolidated
Financial Statements for the quarterly period ended June 30,  2006.
99.5
Core Laboratories N.V. Consolidated
Financial Statements for the quarterly period ended September 30, 2006.